| TERUMO CardioVascular Systems Corp. |
|
|
TERUMO CardioVascular Systems Corp. is
based in Ann Arbor,
Michigan.
Our USA office covers
all sales, marketing
and customer service
activities within
the USA.
Our dedicated
team is available
to take your orders
and deal with
your technical
requests.
|
|
| |
| VASCUTEK,
a TERUMO Company |
| Vascutek
is one of the world's
leading designers, manufacturers
and marketers of vascular
products for the treatment
of cardiovascular disease. |
|
|
Based
at a custom built
facility in Scotland,
Vascutek uses innovative
vascular technologies
to develop products
that address the
needs of cardiovascular
and vascular surgeons
throughout the world.
The company markets
a wide range of
sealed and unsealed
polyester and ePTFE
vascular prosthetic
grafts for the treatment
of diseased and
damaged arteries.
The grafts are sealed
with a specially
modified gelatin,
eliminating the
need for pre-clotting.
|
|
|
| 1996
saw the launch of a
new fluoropolymer/polyester
composite prosthesis,
Fluoropassiv™.
The patented Fluoropassiv™
technology has a unique
fluoropolymer coating,
resulting in lowered
thrombogenicity and
enhanced healing properties.(1-5).
In 1999, the first gelatin
sealed ePTFE graft was
introduced. SEALPTFE™
offers many unique benefits
over ePTFE currently
available. This was
followed in 2001 with
the introduction of
Taperflo™, the
gelatin sealed tapered
variant. Research is
also underway on developing
an endovascular device.
Since the formation
of the original company
in 1982, Vascutek has
grown significantly
and its sales success
has been recognized
by the governments of
the UK and Japan. Vascutek
has been complying for
many years with worldwide
regulatory authorities
and was one of the first
medical device manufacturers
to affix the CE mark
to its products.
Vascutek is guided by
an ethos of technical
excellence, stringent
quality control and
total customer service.
Our aim is to respond
to the needs of surgeons
and patients.
|
|
| Whatever
the customer wants, we
will do our best to provide.
|
| Vascutek
has a continuous program
of Research and Development
and will maintain communication
with surgeons around the
world so that we deliver
the right products from
innovation you can trust.
We will also continue
to make our manufacturing
expertise available for
Original Equipment Manufacture
(OEM). |
|
| References |
1.
Ashton T et al.
Platelet Thrombogenic
Response to Polyester
can be Passivated by Fluoropolymer
Surface Treatment.
European Society for
Biomaterials, (1995). |
2.
Rhee Y et al.
Experimental Evaluation
of Bleeding Complications,
Thrombogenicity and Neointimal
Characteristics of Prosthetic
Patch Materials used for
Carotid Angioplasty.
Cardiovascular Surgery.
(1996) Vol 4, No. 6, 746-752. |
3.
Chinn JA et al.
Blood & Tissue
Compatibility of Modified
Polyester: Thrombosis,
Inflammation and Healing.
J. Biomed. Mat. Res.
(1998), Vol 39, 130-140. |
4.
Curti T et al.
Biocompatibility of
the New Fluoropassiv Vascular
Prosthesis – Ultrastructure
Analysis.
Giornale Italiano di
Chirurgia Vascolare (1994),
Vol. 1, No. 1-2, 27-30. |
5.
Guidoin R et al.
The Benefits of Fluoropassivation
of Polyester Arterial
Prostheses as Observed
in a Canine Model.
American Society for
Artificial Internal Organs
(1994), Vol. 40, No. 3,
M870-879. |
|
